Criteria for the use of omics-based predictors in clinical trials

  • McShane L
  • Cavenagh M
  • Lively T
 et al. 
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


The US National Cancer Institute (NCI), in collaboration with scientists representing multiple areas of expertise relevant to 'omics'-based test development, has developed a checklist of criteria that can be used to determine the readiness of omics-based tests for guiding patient care in clinical trials. The checklist criteria cover issues relating to specimens, assays, mathematical modelling, clinical trial design, and ethical, legal and regulatory aspects. Funding bodies and journals are encouraged to consider the checklist, which they may find useful for assessing study quality and evidence strength. The checklist will be used to evaluate proposals for NCI-sponsored clinical trials in which omics tests will be used to guide therapy. © 2013 Macmillan Publishers Limited. All rights reserved.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • L.M. McShane

  • M.M. Cavenagh

  • T.G. Lively

  • D.A. Eberhard

  • W.L. Bigbee

  • P.M. Williams

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free